ArticleInfluenza and other respiratory viruses2025
Effectiveness and Impact of Autumn 2023 COVID-19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness and Impact of Autumn 2023 COVID-19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveWe aimed to estimate autumn 2023 COVID-19 vaccine effectiveness (CVE) in preventing hospitalizations due to COVID-19 until September 2024.
methodsWe performed a test-negative case-control study nested in the cohort of adults aged ≥ 45 years with indication of autumn 2023 COVID-19 vaccination in Navarre, Spain. The study included patients hospitalized for severe acute respiratory infection (SARI) and tested by polymerase chain reaction between October 2023 and September 2024. The COVID-19 vaccination statuses in the current and previous seasons were compared between confirmed COVID-19 cases and test-negative controls. CVE was estimated as (1 - adjusted odds ratio) × 100.
resultsOf 4051 SARI hospitalized patients included in the study, 474 (12%) were confirmed for COVID-19. CVE to prevent COVID-19 hospitalizations was 32% (95% confidence interval [CI], 11%-48%) on average for the year and 38% (95% CI, 17%-54%) among people aged ≥ 65 years. However, estimates for current-season vaccination were 51% (95% CI, 30%-66%), 50% (95% CI, 16%-70%), and 0% (95% CI, -42% to 30%) for 7 to 89, 90 to 179, and ≥ 180 days between vaccination and COVID-19 diagnosis, respectively. The residual effect of previous-season vaccination was not statistically significant (14%; 95% CI, -20% to 39%). CVE was moderate in preventing COVID-19 hospitalizations between October 2023 and March 2024 (50%; 95% CI, 28%-65%), and null between April and September 2024 (6%; 95% CI, -41% to 38%). The vaccine averted 19% of COVID-19 hospitalizations. On average, 963 doses of vaccine were necessary to prevent one COVID-19 hospitalization.
conclusionsCVE was moderate in preventing COVID-19 hospitalizations during the 2023-2024 season, but decreased 6 months after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.